Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4244MR)

This product GTTS-WQ4244MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4244MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ119MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ15970MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ8046MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ12929MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ10342MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ10473MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ10967MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ12179MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW